STOCK TITAN

IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
IdeeLab Biotechnology partners with Ginkgo Bioworks to enhance biological solutions for agriculture. IdeeLab will provide local strain discovery and manufacturing capabilities to Ginkgo's customers, enabling the development of next-generation products in Brazil's biologicals market.
Positive
  • None.
Negative
  • None.

The partnership between IdeeLab Biotechnology and Ginkgo Bioworks represents a strategic move in the biotechnology and agricultural sectors. By leveraging IdeeLab's local strain discovery and manufacturing capabilities, Ginkgo Bioworks is poised to enhance its cell programming and biosecurity platform. The integration of IdeeLab's facilities will allow Ginkgo to offer a more comprehensive suite of services, from discovery through to manufacturing, which could streamline the R&D process for clients. This is particularly pertinent in the context of the Brazilian market, where the demand for sustainable agricultural solutions is growing.

The mention of IdeeLab's forthcoming GMO-certified plant for ag input metabolites and proteins indicates a significant advancement in sustainable agriculture. The capacity to produce these next-generation biocontrol products at scale could disrupt the conventional agrochemical market, offering potentially safer and more effective alternatives. For investors, this may signal long-term growth opportunities as the adoption of such biological solutions increases.

From a financial perspective, the alliance is likely to be accretive to Ginkgo Bioworks' revenue streams, as it taps into the burgeoning market for biologicals in Brazil. The expansion of the Ginkgo Technology Network with IdeeLab's unique capabilities could attract new customers and drive R&D outcomes, which may translate into higher sales and market share in the long run. However, investors should consider the capital expenditures associated with scaling up manufacturing facilities and the time required to realize returns from such investments.

Furthermore, IdeeLab's status as the sole plant in Brazil certified to manufacture ag input from GMOs by Q1 2025 presents a competitive advantage. This could lead to first-mover benefits in the Brazilian market, potentially resulting in a stronger foothold for Ginkgo and IdeeLab. The partnership's success hinges on the execution of the integration and the market's reception of the next-generation products.

In terms of industry impact, the collaboration between IdeeLab and Ginkgo Bioworks is indicative of a trend towards consolidation and network formation in the biotech sector. The focus on next-generation agricultural products, such as those derived from GMOs, aligns with global efforts to enhance food security and sustainability. The capacity to deliver these innovations at scale could set a new standard in the industry, potentially influencing regulatory frameworks and consumer perceptions around GMO products.

The 6 million liters of fermentation capacity at IdeeLab's facility underscores the scale at which these companies are operating. It is essential to monitor how this capacity translates into actual production volumes and market penetration. The partnership's ability to navigate regulatory hurdles and effectively market these next-generation products will be critical to their industry impact and financial success.

Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities

PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network.

The Ginkgo Technology Network is a groundbreaking global ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs. Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets.

IdeeLab is leading sustainable agriculture biological products development in Brazil by developing new technologies on behalf of customers for the crop input market. Particularly noteworthy, in Q1 2025, IdeeLab will have the only plant in Brazil certified by regulators to make ag input metabolites and proteins from GMOs, which will enable next-generation products in agriculture, such as metabolite and peptide/protein-based biocontrol products that are potentially safer and more efficacious versus conventional chemicals. The manufacturing facility will eventually reach 6 million liters of fermentation capacity, which is more than enough to enable clients to do commercial derisking before potentially building out fermentation capacity of their own. 

IdeeLab's biotech platforms, pilot-scale facility and industrial setting will complement Ginkgo's cell engineering and discovery capabilities. With IdeeLab, customers can now work with Ginkgo in various capacities such as metabolite and microbial discovery through fermentation scale up, registration, field trialing, and manufacturing a product in the fast-growing Brazilian biologicals market.

Ginkgo will continue to add partners to the Technology Network to further complement its offerings, and enable more clients in Brazil to access and explore the joint capabilities of the integrated Technology Network. Ginkgo is already working with leading product developers in the Brazilian market, and more are expected to join with this new expansion.

Ronaldo José Durigan Dalio, CEO of IdeeLab: "This partnership with Ginkgo will help us leap into the future, and leverages both companies to deliver even more innovative solutions to the Brazilian market in a faster and more efficient way. IdeeLab has been leading the development of the next generation of bio ag input in Brazil, and connecting GInkgo's expertise to ours in this process will also help us explore new routes for improving both industrial production and product field performance for our clients."

Anna Marie Wagner, Ginkgo's SVP, Head of AI and Corporate Development: "IdeeLab has been inspiring a new era in Brazilian agriculture and we're thrilled to welcome them to the Ginkgo Technology Network! Adding IdeeLab to our network now gives us the complete, end-to-end ability to deliver ag biological products for customers, especially next-generation products that are based on proteins, peptides and metabolites."

About IdeeLab Biotechnology 

IdeeLab is a fast-growing innovative ag biotechnology company in Brazil, focused on developing disruptive biological technologies and products for sustainable and regenerative agriculture, including biocontrol of pests and diseases, induction of plant resistance/tolerance responses,biostimulation, nutritional cycling and modulation of biotic/abiotic stress in major crops. Our multidisciplinary approach enables us to address emerging needs of the global agriculture market, providing biotechnology-as-a-service along different stages of R&D, from Bioprospection and Discovery, to Agronomical Validation and Go-to-Market (scale up, formulation, shelf-life/quality control, technology transfer, and manufacturing). Our expertise in phytopathology, plant physiology, and biochemistry, and our laboratories and bioprocess facilities are tailored to serve the development of ag inputs based on microbial cell growth/spore titers, as well as metabolites, peptides/proteins, interference RNA, CRISPR-edited, and other GM-derived microorganisms. We are expanding these capabilities to an industrial setting dedicated exclusively to B2B production (white label), to be inaugurated at the end of 2024. For more information, visit www.ideelab.com.br, or follow us on social media channels Instagram
(@ideelab_biotech) and LinkedIn (www.linkedin.com/company/ideelabbr/).

IDEELAB BIOTECHNOLOGY CONTACT:

contato@ideelab.com.br

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo's biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com

GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideelab-joins-the-ginkgo-technology-network-to-provide-agriculture-companies-in-brazil-with-end-to-end-product-development--manufacturing-service-302109679.html

SOURCE IdeeLab Biotechnology

IdeeLab Biotechnology has entered into an agreement with Ginkgo Bioworks (NYSE: DNA) to join the Ginkgo Technology Network.

IdeeLab will offer local strain discovery and manufacturing facilities for the development of next-generation products in agriculture.

IdeeLab will be the only plant in Brazil certified to produce ag input metabolites and proteins from GMOs, enabling the creation of safer and more efficacious biocontrol products.

The partnership will allow both companies to deliver innovative solutions to the Brazilian market more efficiently, combining IdeeLab's expertise in bio ag input with Ginkgo's capabilities.

Ginkgo aims to integrate its network partners' technological capabilities to provide customers with end-to-end solutions for successful R&D outcomes across biological end markets.
Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

DNA Rankings

DNA Latest News

DNA Stock Data

2.13B
1.12B
6.74%
83.82%
12.58%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.